Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Status:
Active, not recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth
of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients. Secondary objectives
include determining if RAD001 treatment will improve hearing ability in NF2 patients.
RAD001 is an oral drug that is approved by Food and Drug Administration (FDA) for other types
of tumors, it is not approved by the FDA for treatment of NF2 related tumors.